March 2014
In This Issue
Stay Connected

Like us on FacebookFollow us on TwitterView our profile on LinkedIn
A Note from Jennifer
Dear WIPO Re:Search Members and Friends, 


It has been a busy month for BVGH and WIPO Re:Search. With six new agreements finalized, the Consortium has surpassed its 50th collaboration.
BVGH finalized two publications presenting WIPO Re:Search achievements: the 2012-2013 WIPO Re:Search Partnership Stories and the 2013 Partnership Hub Annual Report. Both documents are available on our website. 
Roopa, Katy, and I visited the University of British Columbia to meet with researchers from several of its impressive groups, including the Neglected Global Diseases Initiative. It was a great opportunity to see the University's beautiful and growing campus and to learn about the innovative infectious disease research being performed there.
I am pleased to welcome our newest Member, Kineta®, to WIPO Re:Search. 
As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas. 


 Jennifer Dent

President, BVGH 


SpecialSpecial Announcement

The 2012-2013 WIPO Re:Search Partnership Stories booklet is now available! This publication features 26 WIPO Re:Search collaborations and two of the hosting opportunities facilitated by BVGH, WIPO, and the Australian government. The individual stories describe the formation of these collaborations and their early results and successes. Click here to download the booklet.
BVGH also completed its 2013 Partnership Hub Annual Report. The report documents BVGH's achievements and activities. New this year, the report features a Collaboration Pipeline Chart, which tracks each research program's status and development. WIPO Re:Search Members and followers can see where each collaboration began and monitor  research and development progress. The Collaboration Pipeline Chart will be updated regularly by BVGH and can be found on our website. Click here to download the Report.
statsWIPO Re:Search Statistics


 Six new collaborations were finalized last month, including the following:


The University of California, San Francisco (UCSF) will determine the EC50 of Stanford's set of anti-Leishmania peptides. Promising peptides will be assayed for their effect on the morphology of the parasite.




Pfizer agreed to provide PATH and The University of Vermont (UVM) with a compound to test a specific therapeutic hypothesis in an animal model of diarrheal disease.   







GlaxoSmithKline will provide the National Institute of Immunology in India with kinase inhibitors to test against liver-stage malaria parasites.    

PHCPartnership Hub Central 




Jennifer Dent, Roopa Ramamoorthi, and Katy Graef visited the University of British Columbia (UBC) last month. During the visit, they met with several researchers, including Hongshen Ma, Assistant Professor, Mechanical Engineering, Robert Hancock, Director, Centre for Microbial Disease and Immunity Research, and Kishor Wasan, Director, Neglected Global Diseases Initiative (NGDI-UBC). During their visit, the BVGH team discussed the scientists' current research interests and suggested potential partnership opportunities with WIPO Re:Search Members.  



From left to right: Brett Sharp, University-Industry Liaison Office, Roopa Ramamoorthi, Katy Graef, Kishor Wasan, Neglected Global Diseases Initiative (NGDI-UBC), Robert Hancock, Centre for Microbial Disease and Immunity Research, and Jocelyn Conway, NGDI-UBC.
memberNew Member Announcement

This month, we are pleased to announce that Kineta® has joined WIPO Re:Search.
Located in Seattle, Kineta is a nationally-recognized biotechnology company focused on developing cutting-edge therapeutics for autoimmune diseases, viral diseases, and chronic pain. Kineta has developed several small molecule anti-viral candidates that target the innate immune system. These molecules may be useful against a range of viruses, including influenza, dengue, and West Nile viruses. The biotechnology company is also utilizing its innate immune response platform to design adjuvants for both therapeutic and preventative vaccines.
"Partnership is a core element of our drug development strategy and values at Kineta," says Charles Magness, CEO and President of Kineta. "Our team looks forward to leveraging the WIPO Re:Search network and BVGH's support to help advance our vaccine and neglected disease programs."
RequestResearch Request
 WIPO Re:Search Supporter Member, the Council on Health Research for Development (COHRED) is continuing their work aimed at building negotiation capacity in research contracting for organizations in low-to-middle-income countries (LMICs). COHRED is compiling case studies of experiences from individuals living in LMICs that demonstrate various approaches to negotiating fair and equitable research contracts. If you have a contracting experience you wish to share, please contact Jacintha Toohey.
HCHighlighted Contributions  
Featured this month are three contributions submitted by the University of South Florida (USF) to the WIPO Re:Search Database
Synthetic Duffy binding protein-based vaccine 
USF has developed a novel synthetic vaccine based on the ligand domain of the P. vivax Duffy binding protein (DBP). The vaccine elicits antibodies with functional activity against broader allelic variants of the DBP, and favors boosting responses against conserved protective epitopes. 


Novel compound for development of anti-malarial drug

USF has developed a compound that displays potent anti-malarial activity and improved chemical resistance to multi-drug resistant malaria parasites. The 4(1H)-quinolone has shown activity at concentrations as low as 0.15nM against multi-drug resistant P. falciparum.



Nanoparticles to enhance antibiotic delivery and performance

These nanoparticles protect and promote the delivery of antibiotic drugs. Antibiotic drugs are either chemically bonded to, or encapsulated by, the polyacrylate nanoparticles. These nanoparticle antibiotics are morphologically consistent and enhance bioactivity of water-soluble and water-insoluble antibiotics. These nanoparticles have also been tested for their delivery of anti-malarial drugs.  

The full description of these contributions will be available within the Database soon.


For more information or to discuss potential collaborations regarding this technology, please contact Roopa Ramamoorthi.  

newsWIPO Re:Search in the News

The Nigerian Law Intellectual Property Watch website highlighted the WIPO Re:Search video featuring Wellington Oyibo, Associate Professor, College of Medicine, University of Lagos. The article and video can be seen here.
WIPO Director General, Francis Gurry, mentioned WIPO Re:Search during an interview that was published during the lead-up to the WIPO Coordination Committee's nomination of the future WIPO Director General. 
EventsTableUpcoming Global Health Events

Event Title
Web Link
Mar. 16-21Extending the Antibiotic Era - Gordon Conference
Ventura, CA
Mar. 30 - Apr. 4Novel Therapeutic Approaches to Tuberculosis - Keystone Symposium
Keystone, CO
Apr. 2-5
16th International Congress on Infectious Diseases
Cape Town, South Africa

Are you attending a global health event?
Do you have a Research Request to highlight in the Snapshot?

We want to hear from you! Please send feedback and suggestions via email.

WIPO Re:Search Pharmaceutical Members
 *known as Merck in the US and Canada

Copyright © 2012. All Rights Reserved.